Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany
Open Access
- 17 June 2026
- journal article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 20 (6) , e70274
Abstract
After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction. RSV severity decreased with fewer RSV‐associated ICU admissions and shorter hospital stays. RSV sequence analysis identified four known polymorphisms in the nirsevimab binding site among inpatients; none associated with resistance. These findings indicate that nirsevimab effectively reduced medically attended RSV disease in infants.Keywords
Funding Information
- Bundesministerium für Gesundheit (D82015)
- European Centre for Disease Prevention and Control (2021/PHF/23776)
This publication has 16 references indexed in Scilit:
- Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024Influenza and Other Respiratory Viruses, 2024
- Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessmentVaccine, 2024
- Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Germany, 2021 to 2023Eurosurveillance, 2024
- A robust, scalable, and cost-efficient approach to whole genome sequencing of RSV directly from clinical samplesJournal of Clinical Microbiology, 2024
- Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in LuxembourgEurosurveillance, 2024
- Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing dataThe Lancet Infectious Diseases, 2023
- Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission ModelInfectious Diseases and Therapy, 2021
- Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsNew England Journal of Medicine, 2020
- Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897The Journal of Infectious Diseases, 2018
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infantsScience Translational Medicine, 2017